Actively Recruiting
A Centralized Protocol Evaluating the Safety and Clinical Impact of Amino Acid PET for Brain Tumors
Led by Mayo Clinic · Updated on 2026-04-28
47
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
M
Mayo Clinic
Lead Sponsor
F
Food and Drug Administration (FDA)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are evaluating whether adding 18F-DOPA positron emission tomography (PET)/computed tomography (CT) scans to the standard imaging methods can better guide treatment for patients with brain tumors. This phase II trial aims to see if this combined PET/CT scan improves clinical management in more than half of cases. The study also assesses the safety and how well this imaging technique detects tumors beyond what standard MRI scans show. In this study, patients receive an intravenous injection of the radioactive tracer 18F-DOPA and then undergo a PET/CT scan lasting about 30 minutes on the first day. The PET/CT combines functional imaging from PET with anatomical images from CT in one session. After the scan, patients are monitored for three days to observe any effects and to measure outcomes. Participants will be involved in the initial PET/CT scan procedure and followed for safety and tumor detection outcomes for up to 64 days. Researchers will assess how the scan impacts clinical decisions three days after the scan and monitor any adverse events during this time. The study provides detailed imaging and clinical data to understand the potential benefits and safety of adding 18F-DOPA PET/CT to brain tumor management.
CONDITIONS
Brief Title
An Investigational Scan (18F-DOPA PET/CT) for Improving the Clinical Management of Brain Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 and older
- Diagnosis of a brain tumor
- Indication for amino acid PET imaging, including presurgical evaluation, radiation planning, MRI indeterminate for progression versus treatment effect, or clinical need for enhanced monitoring
- Ability to give appropriate consent or have an appropriate representative available to do so
You will not qualify if you...
- Patient is unable to undergo PET imaging
- Persons who are pregnant or nursing
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 day
Participants receive 18F-DOPA intravenously and undergo a PET/CT scan lasting about 30 minutes to evaluate brain tumors.
1 visit (in-person)
Duration - 3 days
Participants are followed for safety and clinical impact assessments after the PET/CT scan.
Follow-up visits over 3 days
Trial Site Locations
Total: 1 location
1
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905
Actively Recruiting
Research Team
C
Clinical Trials Referral Office
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here